1. Home
  2. SPOK vs PBYI Comparison

SPOK vs PBYI Comparison

Compare SPOK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

N/A

Current Price

$13.27

Market Cap

267.8M

ML Signal

N/A

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

N/A

Current Price

$6.77

Market Cap

263.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPOK
PBYI
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
263.4M
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
SPOK
PBYI
Price
$13.27
$6.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
159.0K
434.7K
Earning Date
02-25-2026
02-26-2026
Dividend Yield
9.39%
N/A
EPS Growth
12.68
59.87
EPS
0.80
0.74
Revenue
$139,739,000.00
$211,995,000.00
Revenue This Year
$4.11
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$16.63
$9.12
Revenue Growth
1.47
N/A
52 Week Low
$12.26
$2.58
52 Week High
$19.31
$7.29

Technical Indicators

Market Signals
Indicator
SPOK
PBYI
Relative Strength Index (RSI) 49.80 61.35
Support Level $13.16 $6.75
Resistance Level $13.84 $7.29
Average True Range (ATR) 0.29 0.34
MACD -0.01 0.01
Stochastic Oscillator 40.24 63.41

Price Performance

Historical Comparison
SPOK
PBYI

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: